Also listed on Mirati Therapeutics, Inc., an earlier holder on the record.

Term ends May 17, 2037 · High confidence

Computed 20-year base term

Held by Array BioPharma Inc.

Filed Oct 29, 2018 as application 16/173,726 · Granted Apr 28, 2020

Base term, 20 years from filing

Today

20 years from filing

Term ends May 17, 2037

2017 2037

Clock starts
May 17, 2017

Term ends
May 17, 2037

Granted
Apr 28, 2020

base term fee events Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

None

Term adjustment

No prosecution delay on this record.

No effect

Terminal disclaimer

Resolved from the filed document, referencing US 10,125,134, to May 17, 2037. The term already ends on or before that date, so the cap shortened nothing.

1 of 3

Maintenance fees paid

Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.

Family applications on record here

Applications sharing this one's continuity chain whose file history this site holds. The family may have others.

This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 1 of 3 maintenance fees is paid so far. Confidence: High. from the record

How we calculated this date

One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.

Step	Input	Date after this step	Confidence
Base term, 20 years from filing	Clock starts May 17, 2017, when application PCT/US2017/033099, the earliest non-provisional in its chain, was filed (this one was filed Oct 29, 2018)	May 17, 2037	High confidence
Continuity chain	Every parent in the chain resolved	no change	High confidence
Patent term adjustment	None on file	no change	High confidence
Terminal disclaimer cap	Disclaimer resolved from the filed document (refs US 10,125,134)	resolves to May 17, 2037, no earlier than this term, so no change	High confidence
Patent term extension	None on file	no change	High confidence
Fee events	1 of 3 maintenance fees paid	In force	High confidence
Computed term end	The steps above, in order	May 17, 2037	High confidence

This family

Application PCT/US2017/033099	PCT application no patent term	no patent term
US 10,125,134	In force May 2037	May 2037
US 10,633,381	this patent May 2037	May 2037
US 11,267,812	In force May 2037	May 2037

The applications whose file history this site holds. The family may have others.

Sources

Google Patents · The patent document at USPTO · Assignment records at USPTO

USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup

Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.

Free plan: 3 watched companies. Pro: unlimited.

Alerts on its grants, lapses and transfers.

What's changing

May 2037

Term ends May 17, 2037. Maintenance fees still fall due before then

Terminal disclaimer

A terminal disclaimer resolved from the filed document, referencing US 10,125,134, ends no earlier than this term, so it caps nothing.

Citations

later US patents cite this one

That is top 25% of utility patents granted in 2020 in our data, the only group it is compared against. How we rank

Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.

Kras G12C Inhibitors